SUMMARY The factors influencing the response of essential tremor to prolonged administration of propranolol (120 mg daily for two weeks followed by 240 mg daily for a further two weeks) were investigated in a double-blind, cross-over, placebo-controlled study in 16 patients. Hand tremor was assessed by means of accelerometers with off-line computer analysis. Propranolol was found to be superior to placebo only at the higher dosage regimen (240 mg daily). At this dosage, the median reduction in tremor amplitude (as compared to the control value) was by 45%. The response to the drug (expressed as percentage change in tremor amplitude) was correlated positively with the control amplitude (r, = 0.71, p < 0 01) and negatively (but more weakly) with the control peak frequency of tremor (r, = -0 53, p < 0.05). In the patients with hand tremor greater than 6 x 10-3 cm hand displacement the tremor amplitude was reduced by 65%, as compared to only 17% in patients whose tremor amplitude was below this limit. No statistically significant relationship could be found between percentage change in tremor amplitude and duration of the disorder, age of the patients, degree of cardiac ,8-blockade or serum propranolol levels. The results suggest that patients with small tremor amplitude should not be treated with propranolol unless their tremor becomes severely aggravated under conditions of excessive adrenergic discharge.
The 8-adrenoceptor antagonist propranolol is the drug of first choice in the symptomatic control of essential tremor but not all the patients respond'-3 and a wide range of individual responses are reported. [4] [5] [6] In the past attempts have been made to identify factors potentially useful in predicting the therapeutic outcome. Dupont et all and Murray7 found that the effect of chronic propranolol treatment was better in younger patients and in those with shorter duration of tremor. This contrasts with the observations of Teravainen et a12 and Larsen8 who found propranolol treatment more effective in older patients and in those with lower frequency of tremor. In our previous study,9 patients with larger amplitude and lower frequency of tremor showed a better response to a single oral dose of propranolol (120 mg) than those with smaller amplitude and higher frequency. The present investigation was designed to verify whether the same factors are of value in predicting the therapeutic efficacy of propranolol following chronic administration.
Methods
Patients Sixteen patients with mild to severely disabling essential tremor (8 male and 8 female) aged between 20 and 72 years (mean age 43 years) and attending the outpatient clinics at the National Hospital for Nervous Diseases, Queen Square, gave their informed consent to participate in the study. The diagnosis was established on the basis of the clinical history and detailed general and neurological examination, accompanied by ancillary laboratory investigations where necessary. All patients had been symptomatic for at least one year prior to the study.
In nine patients there was a family history of tremor affecting the hands and/or the head. Fifteen patients had previously taken part in a single oral dose study with propranolol.9 None of the patients was receiving any drug therapy for tremor at the time of the study but nine of them 393 had been previously treated with propranolol (dose range 80-240 mg daily). Patients with a history of excessive alcohol consumption, congestive cardiac failure, heart block, diabetes mellitus and asthma were excluded. Protocol The study was crossover, randomised, doubleblind and placebo-controlled. In addition to propranolol and placebo, each patient was also given a course of metoprolol, 150 mg daily for two weeks followed by 300 mg daily for two weeks. (Details on the comparative efficacy of metoprolol and propranolol are reported elsewhere'0). Each treatment period lasted for 4 Two patients had placebo discontinued after a period of two weeks because tremor interfered seriously with their daily activities. The frequency of the dominant peak of hand tremor in the patients studied ranged from 4-2 to 10-0 Hz (median 7-2 Hz). In any individual patient, the tremor peak frequency showed some variation on the two different occasions of recording but when all patients were considered the difference was not statistically significant. The magnitude of hand tremor at the dominant peak frequency ranged from 1-3 to 236 g X 10-3, which in terms of hand displacement corresponds to 0*6 to 270 x 10-3 cm amplitude (median 4*7 x 10-3 cm). There was an inverse correlation between the amplitude and the frequency of the tremor (r, = -0*65, p < 0-05) (Fig 1) whereas age of the patients and duration of the disorder did not correlate with either amplitude or frequency of tremor (data calculated on the 4th week of placebo treatment).
In four patients the tremor amplitude during the 2nd week of placebo was found to be lower than 2 x 1 0-3 cm, that is the upper limit of physiological hand tremor in our laboratory (unpublished data). All patients had pathological values of tremor amplitude during the 4th week of placebo treatment.
THE EFFECT OF PROPRANOLOL ON TREMOR FREQUENCY AND AMPLITUDE
Only 13 patients received propranolol at higher dosage. The drug was discontinued after two weeks of treatment in two patients because of breathlessness and for failure to attend the clinic in a further patient.
There was no significant differences between the 
Discussion
In the present study, propranolol was found to produce a decrease in tremor amplitude (as compared to placebo) greater than 20% in eight out of 16 patients at a daily dosage of 120 mg and in nine out of 13 patients at a daily dosage of 240 mg, the maximum effect being a reduction down to 13% of the control value. The dosages included in this investigation are within the range commonly employed in the treatment of essential tremor and, according to Jefferson et al,4 they are also those at which the optimum therapeutic benefit is usually seen. Taken altogether, the results are in agreement with previous reports that only about two thirds of the patients with essential tremor respond to propranolol when the drug is given on a daily basis'-3 and that the degree of the response is variable and usually incomplete."
The most interesting finding of our study is the demonstration that the response of essential tremor to prolonged administration of propranolol is a function of the tremor amplitude, at least in patients whose amplitude, in the absence of active treatment, exceeds 6x 10-3 cm hand displacement. In patients with lower amplitudes, the clinical response was unpredictable and attenuated (median decrease in tremor amplitude 17%, as compared to 65% in the larger amplitude group). This differential response to propranolol could not be ascribed to pharmacokinetic factors, since serum propranolol levels and degree of cardiac ,-blockade were similar in the two groups.
The tendency for the response to chronic propranolol administration to be more favourable in patients with lower frequency of tremor is likely to reflect the inverse correlation between amplitude and frequency of tremor (see Results).
These findings are in contrast with those reported by Sorensen et al,6 who showed the degree of tremor reduction after prolonged administration of propranolol to be independent of its amplitude. These authors, however, studied only five patients, a group probably too small to allow a meaningful estimate of the factors affecting the response to the drug. In contrast with previous studies, 1 2 78 we were not able to find any significant correlation between response to the drug and age of the patients or duration of the disorder. The fact that in our study the response to propranolol did not correlate with the serum concentration of the drug is in agreement with the results reported by others.4 '6 All patients but one had previously taken part in a single-dose study on the effect of propranolol in essential tremor.9 Since the same methods of assessment were used on that occasion, a comparison between the results obtained in the two studies is of considerable interest. In agreement with the data obtained in the chronic situation, the response observed after a single dose of propranolol was better in the patients with larger tremor amplitude. On the whole, the efficacy of the drug was greater after acute than after chronic administration. It is particularly noteworthy that after acute administration propranolol was clearly superior to placebo in reducing essential tremor at a dose of 120 mg, whereas during prolonged treatment the effect was evident only at a dosage of 240 mg daily. It is reasonable to assume that this discrepancy may be due mainly to differences in the experimental design (in the acute study propranolol was given as a single dose and not as three divided doses), resulting in different serum levels of the drug. Indeed, serum concentrations of propranolol in the range of that obtained following a single oral dose (120 mg)9 were achieved with 240 mg of the drug when given chronically. Nevertheless a higher prevalence of the "placebo effect" after prolonged administration of the drug could partially account for this differential response.
On the basis of the response to acute and chronic propranolol administration it may be postulated that there are at least two subtypes of essential tremor. The first one, characterized by smaller amplitude and usually (but not necessarily) higher peak fre-cal tremor (for example, the tremor seen after catecholamines infusion, stress etc) in that it does not respond to acute and chronic propranolol. The second subtype of essential tremor, showing larger amplitude and usually (but not necessarily) lower peak frequency, responds to adequate doses of oral propranolol to an extent which is directly proportional to its amplitude. Whether the two subtypes are separate pathological entities or a continuum, the more severe form simply representing the progression of the same disorder, is unknown and deserves further investigation. The lack of reponsiveness of one subtype to propranolol may underline the existence of separate pathophysiological mechanisms or simply reflect the inability of the drug to affect any type of tremor when the amplitude is below a given "cut-off' value.
One important question from the practical point of view is whether patients with small amplitude of essential tremor should be treated with propranolol. Our findings clearly indicate that such tremor does not respond to the drug. It should be pointed out, however, that in many of these patients the tremor can be aggravated and become severely disabling under conditions associated with adrenergic stimulation (for example, anxiety and stress). Since this "secondary" exaggeration is known to respond to ,8-blockers,'6 the choice whether to treat or not to treat should depend on careful evaluation of the medical history, with particular regard to the identification of precipitating factors. 
